| Not Yet Recruiting | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies NCT07282548 | Ipsen | — |
| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Not Yet Recruiting | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers NCT07226843 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma NCT07299149 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Not Yet Recruiting | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recur NCT07187960 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in NCT07191249 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Recruiting | Odronextamab in Low Tumor Volume Advanced FL NCT07128641 | Gottfried von Keudell, MD PhD | Phase 2 |
| Withdrawn | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Foll NCT06068881 | Epizyme, Inc. | Phase 2 |
| Recruiting | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investi NCT06911502 | Celgene | Phase 3 |
| Recruiting | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular NCT07126678 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Not Yet Recruiting | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma NCT07024147 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas NCT07029217 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Folli NCT06918015 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follic NCT06830759 | AbbVie | — |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma NCT06826118 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleuc NCT06794268 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | — |
| Recruiting | Epco, Zanu, Ritux for R/R FL or MZL NCT06563596 | Reid Merryman, MD | Phase 2 |
| Recruiting | CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638 | RenJi Hospital | N/A |
| Recruiting | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma NCT06704555 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lympho NCT06549335 | Ruijin Hospital | Phase 2 |
| Recruiting | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy NCT06510361 | Beth Israel Deaconess Medical Center | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients NCT06492837 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Not Yet Recruiting | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research NCT06049485 | Power Life Sciences Inc. | — |
| Recruiting | Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin NCT06813573 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma NCT06284122 | The Lymphoma Academic Research Organisation | Phase 3 |
| Recruiting | Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immun NCT06070961 | Fondazione Italiana Linfomi - ETS | — |
| Active Not Recruiting | A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients Wi NCT06742879 | Zhengzhou University | — |
| Recruiting | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas NCT06350318 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Not Yet Recruiting | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma NCT06368167 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Recruiting | Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma NCT06553352 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Active Not Recruiting | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular NCT06108232 | M.D. Anderson Cancer Center | Phase 2 |
| Suspended | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma NCT06112847 | City of Hope Medical Center | Phase 2 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Recruiting | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Co NCT06043323 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. NCT06424379 | Hospices Civils de Lyon | — |
| Not Yet Recruiting | Relmacabtagene Autoleucel in Hematologic Malignancies NCT06142188 | Shanghai Ming Ju Biotechnology Co., Ltd. | — |
| Recruiting | Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: NCT05929222 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies NCT05541341 | Novartis Pharmaceuticals | — |
| Recruiting | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Active Not Recruiting | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma NCT05994235 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Not Yet Recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502 | Ruijin Hospital | — |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Recruiting | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas NCT05934838 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 NCT05816850 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas NCT05365659 | Iksuda Therapeutics Ltd. | Phase 1 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Withdrawn | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma NCT05867030 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma NCT05783596 | Reid Merryman, MD | Phase 2 |
| Recruiting | Epcoritamab and Rituximab for First-line Follicular Lymphoma NCT05783609 | Reid Merryman, MD | Phase 2 |
| Terminated | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma NCT05618366 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621 | Ruijin Hospital | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves NCT05512390 | AbbVie | Phase 1 |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Active Not Recruiting | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers NCT05749549 | Shanghai Blueray Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Active Not Recruiting | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096 | University of Nebraska | Phase 1 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor B NCT05551936 | Vaishalee Kenkre | Phase 1 / Phase 2 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Withdrawn | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma NCT05934097 | Fate Therapeutics | Phase 1 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Terminated | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT05611853 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Completed | Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) NCT05529524 | The Lymphoma Academic Research Organisation | — |
| Recruiting | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Stud NCT05846763 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Active Not Recruiting | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma NCT05410418 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an NCT05458297 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502 | Brown University | Phase 2 |
| Unknown | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma NCT05444322 | He Huang | EARLY_Phase 1 |
| Recruiting | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354 | Adaptive Biotechnologies | — |
| Recruiting | A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma NCT05389293 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy NCT05414162 | University Hospital, Bonn | — |
| Recruiting | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P NCT05294731 | BeiGene | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lym NCT05326308 | iOMEDICO AG | — |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Active Not Recruiting | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma NCT03361852 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy NCT05064787 | Pack Health | N/A |
| Unknown | A Phase II Trial of Intermediate Radiation Dose For Lymphoma NCT05284825 | Sunnybrook Health Sciences Centre | N/A |
| Completed | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Recruiting | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lympho NCT04998669 | Juan P. Alderuccio, MD | Phase 2 |
| Terminated | Study of Copanlisib and Ketogenic Diet NCT04750941 | Columbia University | Phase 2 |
| Completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies NCT04599634 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High NCT05058404 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Unknown | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 |
| Unknown | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma NCT05020392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Terminated | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma NCT04722601 | University of Chicago | Phase 1 / Phase 2 |
| Active Not Recruiting | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy NCT04962126 | Olivia Newton-John Cancer Research Institute | Phase 2 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Unknown | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular NCT04989621 | Sun Yat-sen University | Phase 2 |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Recruiting | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgki NCT04669171 | Enterome | Phase 1 / Phase 2 |
| Not Yet Recruiting | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular NCT02194751 | XEME Biopharma Inc. | Phase 2 |
| Unknown | B-cell Chronic Lymphoid Malignancies Markers NCT04952974 | University Hospital, Strasbourg, France | — |
| Completed | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell NCT05784415 | AIDS Malignancy Consortium | — |
| Completed | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymp NCT04918940 | Centre Henri Becquerel | N/A |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Terminated | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035 | TG Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Place NCT04680052 | Incyte Corporation | Phase 3 |
| Completed | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma NCT04849351 | Hutchison Medipharma Limited | Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Recruiting | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma NCT04594642 | AstraZeneca | Phase 1 |
| Unknown | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter NCT04842318 | Ruijin Hospital | Phase 4 |
| Completed | Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Regio NCT04859920 | Centre Hospitalier Universitaire Dijon | — |
| Active Not Recruiting | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy NCT04745559 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma NCT04379167 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 |
| Terminated | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory NCT04762160 | Epizyme, Inc. | Phase 2 |
| Terminated | Study of LUCAR-20S in Patients With R/R NHL NCT04176913 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Withdrawn | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity NCT04503538 | Wake Forest University Health Sciences | N/A |
| Completed | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone NCT04508647 | University of Colorado, Denver | Phase 2 |
| Recruiting | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapse NCT04223765 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) NCT04663347 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylin NCT05387616 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the NCT04246086 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma NCT04468841 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination NCT04224493 | Epizyme, Inc. | Phase 3 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Terminated | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas NCT04305444 | Zhejiang DTRM Biopharma | Phase 2 |
| Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL NCT04342117 | SecuraBio | — |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Unknown | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status NCT04934930 | Meir Medical Center | Phase 2 |
| Unknown | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma NCT04707079 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Unknown | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI NCT04154228 | Tel-Aviv Sourasky Medical Center | N/A |
| Recruiting | Italian Observational Study on CAR-T Therapy for Lymphoma NCT06339255 | Paolo Corradini | — |
| Terminated | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma NCT03890289 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma NCT04082936 | IGM Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) NCT04034056 | Hoffmann-La Roche | — |
| Terminated | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma NCT03919175 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma NCT03789240 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma NCT03980171 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma NCT03828448 | TG Therapeutics, Inc. | Phase 2 |
| Unknown | Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea NCT04048395 | Samsung Medical Center | — |
| Unknown | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma NCT04089215 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registr NCT04587388 | European Hematology Association - Lymphoma Group | — |
| Completed | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB F NCT03976102 | Dr. Reddy's Laboratories Limited | Phase 3 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Terminated | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle C NCT03685344 | ADC Therapeutics S.A. | Phase 1 |
| Unknown | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies NCT03999697 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Unknown | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. NCT03720457 | Hrain Biotechnology Co., Ltd. | Phase 1 |
| Completed | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma NCT03568461 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Trial of Radiotherapy and Durvalumab in DLBCL and FL NCT03610061 | Austin Health | Phase 1 |
| Unknown | R2 in the Treatment of Follicular Lymphoma NCT03715309 | Ruijin Hospital | Phase 2 |
| Terminated | Rituximab + Immunotherapy in Follicular Lymphoma NCT03636503 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma NCT03121677 | Washington University School of Medicine | Phase 1 |
| Completed | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL NCT03806179 | Nordic Nanovector | Phase 1 |
| Terminated | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma NCT03585725 | Weill Medical College of Cornell University | EARLY_Phase 1 |
| Recruiting | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-gener NCT03676504 | University Hospital Heidelberg | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma NCT03600441 | Xynomic Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies NCT03151057 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases NCT03498612 | University of Washington | Phase 2 |
| Completed | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Ta NCT03010982 | Epizyme, Inc. | Phase 1 |
| Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576 | Emory University | — |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously U NCT03374137 | Hoffmann-La Roche | — |
| Active Not Recruiting | Personalized Risk Stratification Model of Follicular Lymphoma Patients NCT03436602 | Oncology Institute of Southern Switzerland | — |
| Unknown | A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma NCT03221348 | Cho Pharma Inc. | Phase 1 |
| Completed | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT03424603 | Sutro Biopharma, Inc. | Phase 1 |
| Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product NCT03436771 | Juno Therapeutics, a Subsidiary of Celgene | — |
| Completed | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas NCT03276468 | The Lymphoma Academic Research Organisation | Phase 2 |
| Unknown | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refr NCT04184414 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Completed | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymph NCT03520920 | BeiGene | Phase 2 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Completed | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Ther NCT03113422 | PrECOG, LLC. | Phase 2 |
| Completed | Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma NCT03381768 | Lars Møller Pedersen | Phase 1 |
| Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells NCT03375619 | Medical College of Wisconsin | — |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Unknown | Constitutional Genetics in Follicular Lymphoma NCT03234140 | Hospices Civils de Lyon | — |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Completed | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL NCT03019666 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study of PLX2853 in Advanced Malignancies. NCT03297424 | Opna Bio LLC | Phase 1 |
| Active Not Recruiting | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A NCT03245021 | Dr. Eliza Hawkes | Phase 1 |
| Completed | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma NCT03078855 | Jonathan Friedberg | Phase 3 |
| Terminated | TGR1202 in Relapsed and Refractory Follicular Lymphoma NCT03178201 | Columbia University | Phase 2 |
| Recruiting | Clonal Evolution in Follicular Lymphoma NCT03190928 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Terminated | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refrac NCT03135262 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT03105336 | Kite, A Gilead Company | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers NCT03037645 | Sunesis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients NCT02877550 | Swiss Cancer Institute | Phase 1 |
| Completed | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma NCT02947347 | Pharmacyclics LLC. | Phase 3 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Terminated | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy NCT02966730 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Unknown | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepa NCT02991638 | The University of Hong Kong | Phase 3 |
| Unknown | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma NCT02819583 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chem NCT02889523 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas NCT02700022 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Unknown | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia a NCT02892695 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymp NCT02851589 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool NCT02791217 | Assuta Medical Center | — |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisi NCT02793583 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Completed | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma NCT02756247 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression NCT03525665 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | Dose Optimization Study of Idelalisib in Follicular Lymphoma NCT02536300 | Gilead Sciences | Phase 3 |
| Completed | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) NCT02631044 | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| Completed | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma NCT02677155 | Oslo University Hospital | Phase 2 |
| Withdrawn | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly NCT02623920 | University of Arizona | Phase 2 |
| Withdrawn | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab a NCT02576275 | SecuraBio | Phase 3 |
| Completed | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lympho NCT02260804 | Celltrion | Phase 3 |
| Terminated | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma NCT02451111 | Swiss Cancer Institute | Phase 2 |
| Unknown | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma NCT02449252 | Wuhan University | Phase 3 |
| Terminated | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Ly NCT02258529 | Gilead Sciences | Phase 2 |
| Completed | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphom NCT02401048 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Terminated | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma NCT02295722 | AHS Cancer Control Alberta | Phase 1 / Phase 2 |
| Completed | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) NCT02303119 | The Lymphoma Academic Research Organisation | Phase 3 |
| Terminated | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Foll NCT02258555 | Gilead Sciences | Phase 1 |
| Completed | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comp NCT02187861 | Hoffmann-La Roche | Phase 2 |
| Completed | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relap NCT02242045 | Gilead Sciences | Phase 1 |
| Completed | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL NCT02142530 | Massachusetts General Hospital | Phase 1 |
| Completed | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients NCT02213263 | Pfizer | Phase 3 |
| Terminated | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular L NCT02204982 | SecuraBio | Phase 3 |
| Terminated | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation NCT02008006 | Centre Leon Berard | Phase 2 |
| Withdrawn | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Unknown | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituxi NCT02423837 | National Research Center for Hematology, Russia | Phase 3 |
| Completed | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma NCT01980654 | Pharmacyclics LLC. | Phase 2 |
| Completed | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) NCT01953692 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma NCT01939899 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapse NCT01799889 | Gilead Sciences | Phase 2 |
| Terminated | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL NCT01728207 | Gilead Sciences | Phase 1 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) NCT01662102 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Completed | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma NCT01796171 | Nordic Nanovector | Phase 1 / Phase 2 |
| Terminated | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) NCT01500538 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Completed | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined NCT01691898 | Genentech, Inc. | Phase 1 / Phase 2 |
| Completed | Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778 | Medical College of Wisconsin | Phase 3 |
| Completed | CD180 Overexpression in Follicular Lymphoma NCT02978898 | Hospices Civils de Lyon | — |
| Completed | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-50 NCT01650701 | The Lymphoma Academic Research Organisation | Phase 3 |
| Completed | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma NCT01476787 | Celgene | Phase 3 |
| Completed | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) NCT01419665 | Sandoz | Phase 3 |
| Terminated | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) NCT01370694 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymp NCT01389076 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014 | University of Rochester | Phase 2 |
| Completed | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas NCT01282424 | Gilead Sciences | Phase 2 |
| Unknown | Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Che NCT01329354 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Terminated | BRIEF Bendamustine and Rituximab In Elderly Follicular NCT01313611 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Ly NCT01275209 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymph NCT01306643 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma NCT01239394 | Massachusetts General Hospital | Phase 2 |
| Completed | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma NCT01393756 | The Lymphoma Academic Research Organisation | Phase 2 |
| Terminated | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma NCT01147393 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Completed | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients Wi NCT00992446 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody NCT01120457 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma NCT01180569 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Withdrawn | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma NCT01460602 | Louisiana State University Health Sciences Center Shreveport | Phase 1 / Phase 2 |
| Terminated | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma NCT01121757 | Duke University | Phase 2 |
| Completed | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT01118845 | SymBio Pharmaceuticals | Phase 2 |
| Completed | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma NCT01078142 | Georg Hess, MD | Phase 1 / Phase 2 |
| Completed | Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma NCT01926639 | Oslo University Hospital | Phase 2 |
| Completed | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients NCT01303887 | University of Liverpool | Phase 3 |
| Terminated | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL NCT00772668 | University of Miami | N/A |
| Terminated | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma P NCT00850499 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants NCT02536664 | Hoffmann-La Roche | — |
| Terminated | Study of Repeat Intranodal Injections of Ad-ISF35 NCT00942409 | Januario Castro, M.D. | Phase 2 |
| Completed | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymp NCT01523860 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Terminated | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma NCT00901927 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell T NCT00880815 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBC NCT04160442 | Carevive Systems, Inc. | N/A |
| Completed | Lenalidomide and R-CHOP in B-cell Lymphoma NCT00901615 | Lymphoma Study Association | Phase 1 / Phase 2 |
| Completed | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Ho NCT00794638 | SymBio Pharmaceuticals | Phase 1 |
| Completed | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Ritux NCT00783367 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Unknown | Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy NCT01151358 | University Hospital, Saarland | — |
| Completed | Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 NCT02461290 | Hoffmann-La Roche | — |
| Unknown | Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According t NCT00722930 | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | Phase 2 |
| Completed | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relap NCT00636792 | Millennium Pharmaceuticals, Inc. | Phase 2 |